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ulticenter Intravascular Ultrasound
alidation Study Among Heart Transplant Recipients
utcomes After Five Years
on A. Kobashigawa, MD, FACC,* Jonathan M. Tobis, MD, FACC,*
andall C. Starling, MD, MPH, FACC,† E. Murat Tuzcu, MD, FACC,†
ndrew L. Smith, MD, FACC,‡ Hannah A. Valantine, MD, FACC,§ Alan C. Yeung, MD, FACC,§
andeep R. Mehra, MD, FACC, Hitoshi Anzai, MD,* Brandy T. Oeser, MPH,*
amal H. Abeywickrama, PHD,¶ Jane Murphy, BSN,¶ Nathalie Cretin, MD¶
os Angeles and Stanford, California; Cleveland, Ohio; Atlanta, Georgia; New Orleans, Louisiana; and
asel, Switzerland
OBJECTIVES We sought to assess the validity of first-year intravascular ultrasound (IVUS) data as a
surrogate marker for long-term outcome after heart transplantation.
BACKGROUND Cardiac allograft vasculopathy (CAV) is a major impediment to long-term graft survival.
Intravascular ultrasound is more sensitive than coronary angiography and detects intimal
thickening (early CAV) in the coronary arteries of the donor heart. Single-center studies have
suggested first-year IVUS results might be a surrogate marker for long-term outcome.
METHODS First-year IVUS results and subsequent five-year clinical follow-up data were reviewed in 125
heart transplant recipients from five institutions. The IVUS tapes (at baseline and one year)
were re-analyzed at a core IVUS laboratory. The change in maximal intimal thickness (MIT)
from baseline to one year was recorded for several matched sites in the same coronary artery.
Patients were classified into two groups: those with0.5 mm in the MIT in any matched site
(group 1) and those with MIT 0.5 mm (group 2).
RESULTS Group 1 patients compared with group 2 patients had a higher incidence of death or graft loss
(D/GL, 20.8% vs. 5.9%; p  0.007), had more nonfatal major adverse cardiac events and/or
D/GL (45.8% vs. 16.8%; p 0.003), and had more findings of newly occurring angiographic
luminal irregularities (65.2% vs. 32.6%, p  0.004).
CONCLUSIONS This multicenter study suggests that progression of intimal thickening 0.5 mm in the first
year after transplantation appears to be a reliable surrogate marker for subsequent mortality,
nonfatal major adverse cardiac events, and development of angiographic CAV through five
years after heart transplantation. (J Am Coll Cardiol 2005;45:1532–7) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.035American College of Cardiology Foundation
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tardiac allograft vasculopathy (CAV) is an accelerated form
f intimal hyperplasia that occurs in the coronary arteries of
he transplanted heart. The precise mechanisms are un-
nown, but both immune and nonimmune mechanisms
ave been implicated. The disease represents the major
mpediment to long-term graft survival. To date, treatment
ptions have been limited due to the often diffuse nature of
he disease, precluding the routine use of percutaneous
ntervention or coronary artery bypass grafting. Symptom-
tically, CAV may lead to congestive heart failure, angina
as a result of allograft reinnervation), and sudden death.
The processes of CAV begin in the donor even before
ransplantation. Perioperative and early postoperative events
ontinue to play a pivotal role in the up-regulation of the
From the *University of California at Los Angeles, Los Angeles, California;
Cleveland Clinic Foundation, Cleveland, Ohio; ‡Emory University, Atlanta, Geor-
ia; §Stanford University, Stanford, California; Ochsner Clinic Foundation, New
rleans, Louisiana; and ¶Novartis Pharma, Basel, Switzerland. This study was
ponsored by a grant from Novartis Pharmaceuticals.g
Manuscript received August 4, 2004; revised manuscript received January 20, 2005,
ccepted February 14, 2005.mmune system, which causes chronic vascular insults. It
ppears that the events of the first year after transplantation
e.g., ischemia, rejection, and infection) may determine the
ecipient’s immune response to the donor heart and the
ubsequent development of CAV. As of yet, there is no clear
urrogate marker for the development of CAV. However,
ecent work has suggested that the first-year intravascular
ltrasound (IVUS) data might provide this information
1–3).
Intravascular ultrasound is an invasive procedure that
etects thickening in the walls of the coronary arteries.
ecause the IVUS catheter provides a sonar image of
ntimal and media thickness, IVUS is more sensitive than
oronary angiography, which only outlines the lumen with
ontrast dye. The coronary angiogram may appear normal,
hereas IVUS reveals significant amounts of atherosclerosis
or intimal thickening) (1,4). Intravascular ultrasound is
erformed during the patient’s angiogram (four to six weeks
fter transplantation and again at one year after transplan-
ation). There have been single-center studies (1–3) sug-
esting that the first-year IVUS results might predict
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May 3, 2005:1532–7 Heart Transplant Multicenter IVUS Studyong-term outcome; however, this has not been established
n a large multicenter study. Therefore, this multicenter
tudy examines whether there are IVUS variables at one year
fter transplantation, which can be used to predict death
nd/or graft loss (D/GL) and nonfatal major adverse cardiac
vents (NF-MACE) in the subsequent five years after
ransplantation.
ETHODS
atients were included in the study if they received a
rimary heart transplant before December 31, 1997, and
urvived at least one year. Patients who had two IVUS
xaminations performed (at four to six weeks after trans-
lantation and at one year after transplantation) from five
eart transplant centers with IVUS experience were in-
luded in the study. Outcome data during five years were
bstracted from medical records. Institutional review board
pproval was obtained at each participating center.
The IVUS tapes (baseline and one-year follow-up) from
ach patient were sent to a core laboratory (University of
alifornia at Los Angeles) for analysis. The IVUS tapes
ere digitized, and quantitative ultrasound measurements
ere made using the Indec computer system (Mountain
iew, California). Approximately three to five matched
ross sections, predominantly in the left anterior descending
oronary artery, from baseline to one-year follow-up, were
tudied. The IVUS cross sections were matched by using
dentifiable landmarks in the images, such as bifurcations or
rterial calcification, or external landmarks, such as coronary
eins or pericardium. In addition, the one-year IVUS
tudies were obtained with an angiographic roadmap of
here the initial IVUS study was performed along the
ength of the vessel. The IVUS system (CVIS Corp.,
unnyvale, California) used was 20 MHz, and a slow,
anual pullback was performed at 1 mm/s from the
id-distal portion of the study vessel, where an easily
dentifiable landmark was visible (i.e., branchpoint). The
ollowing items were measured for each patient: maximal
ntimal thickness (MIT), intimal area (IA), and vessel area,
efined as the border of the external elastic membrane.
ercent area stenosis was then calculated as IA/external
lastic membrane. The IVUS data were reviewed to deter-
Abbreviations and Acronyms
CAD  coronary artery disease
CAV  cardiac allograft vasculopathy
CMH  Cochran-Mantel-Haenszel
CMV  cytomegalovirus
D/GL  death and/or graft loss
IA  intimal area
IVUS  intravascular ultrasound
MIT  maximal intimal thickness
NF-MACE  nonfatal major adverse cardiac eventsine the delta change (comparing baseline to one year) in cntimal thickness. This method accounted for preexisting
onor coronary artery disease (CAD) in the dataset.
The patients were classified into two groups according to
heir MIT (increase from baseline to one year): group 1 had
asculopathy (largest MIT change 0.5 mm); and group 2
ad no vasculopathy (largest MIT change 0.5 mm).
The medical records of these patients were reviewed to
ssess the five-year outcome. This included graft survival,
F-MACE (defined as acute myocardial infarction, con-
estive heart failure, need for percutaneous cardiac interven-
ion, coronary artery bypass grafting, cardiac defibrillator
lacement, cerebral vascular accident, peripheral vascular
isease), and angiographic CAD (any new luminal irregu-
arity and new stenosis 50%).
tatistical analysis. In this retrospective exploratory study,
he study sample were all patients at the participating
enters who had the required IVUS data and five-year
ollow-up outcome data.
The main predictor variable chosen was the largest
hange in MIT from baseline to one year. The progression
f intimal thickening of 0.5 mm was the primary focus of
he investigation and was used to define the presence of
asculopathy. Other predictor variables of interest are the
argest change in IA and the largest change in percentage
rea stenosis. This study examines whether these predictor
ariables at one year after transplantation can be used to
redict NF-MACE or D/GL in the first five years after
ransplantation.
Time to inclusion of patients with and without vascu-
opathy into each group was compared using Kaplan-Meier
urvival methods and the log-rank test. Percentages of
atients in each group with and without vasculopathy were
ompared using the Cochran-Mantel-Haenszel (CMH)
eneral association test, stratified by center. The effects of
asculopathy, correcting for possible covariates, were exam-
ned using Cox regression models. Summary statistics of
ata on demographics, IVUS data, outcome data, laboratory
alues, and treatment were calculated and compared using
he Fisher exact test (categorical data), the CMH test
categorical variables stratified by center), and the van
lteren test (continuous variables stratified by center) (5).
ESULTS
total of 125 primary heart transplant recipients (Univer-
ity of California at Los Angeles [n 49], Cleveland Clinic
oundation [n  44], Stanford University [n  11],
chsner Clinic Foundation [n  6], and Emory University
n  15]) transplanted before December 31, 1997, who had
urvived at least one year and had two IVUS examinations
erformed (at baseline [four to six weeks after transplanta-
ion] and one year after transplantation) were reviewed.
here were 24 patients with MIT progression 0.5 mm
group 1) and 101 patients with MIT progression0.5 mm
group 2). The characteristics of the two study groups were
omparable, except for donor age, which was higher in
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Heart Transplant Multicenter IVUS Study May 3, 2005:1532–7roup 1 (37 12 years vs. 30 13 years; p 0.028) (Table
). Between group 1 and group 2 patients, there was
omparable use of cyclosporine immunosuppression (100%
s. 95%), azathioprine immunosuppression (96% vs. 96%),
ytolytic induction (8% vs. 27%), and use of statins (25% vs.
1%). Total cholesterol, low- and high-density lipoprotein
holesterol levels, as well as the incidence of diabetes, were
imilar between groups. However, triglyceride levels were
ignificantly higher in group 1 versus group 2 patients (168
85 mg/dl vs. 257  177 mg/dl; p  0.025).
Group 1 compared with group 2 patients had a 3.5-fold
igher incidence of D/GL (20.8% vs. 5.9%, p  0.025 by
Table 1. Patient Demographics (n  125)
Characteristics
(M
Median age in yrs (range)
Patient
Donor*
Male gender
Patients with most recent PRA 10%
Patients with CMV mismatch (D/R)
Pre-transplant CAD
Pre-transplant LVAD
Mean (SD)
Cold ischemia time in h
First-year triglycerides (mg/dl)†
*p  0.028, Cochran-Mantel-Haenszel test, stratified by cen
CAD  coronary artery disease; CMV  cytomegalovir
MIT  maximal intimal thickness; PRA  panel reactive aigure 1. Kaplan-Meier curve of death and/or graft loss by maximal intimal thi
MIT change 0.5 mm. Vertical bars   SE.he log-rank test, p 0.007 by the CMH test) (Fig. 1). The
auses of death in group 1 compared with group 2 patients
ere sudden death (4% vs. 1%), congestive heart failure (0%
s. 1%), rejection (0% vs. 2%), malignancy (4% vs. 0%), and
ther (13% vs. 1%).
There were more NF-MACE and/or D/GL in group 1
ompared with group 2 patients (45.8% vs. 16.8%, p 
.001 by the log-rank test, p  0.003 by the CMH test)
Fig. 2). The incidence of NF-MACE alone was also higher
n group 1 compared with group 2 patients (38% vs. 12%).
he causes of NF-MACE in group 1 compared with group
patients were congestive heart failure (13% vs. 2%, p 
Group 2
hange <0.5 mm)
N  101)
Group 1
(MIT change >0.5 mm)
(N  24)
54 (25–71) 56 (33–66)
28 (13–67) 38 (13–62)
82 (81%) 21 (88%)
6 (7%) 1 (5%)
13 (13%) 2 (8%)
50 (50%) 17 (71%)
12 (12%) 5 (21%)
.7 (0.1) 2.7 (0.8)
68 (85) 257 (177)
p  0.025, van Elteren test, stratified by centers.
 donor positive; LVAD  left ventricular assist device;
ies; R  recipient negative; SD  standard deviation.IT c
(
2
1
ters. †ckness (MIT) classification. Group 1  MIT change 0.5 mm; group 2
0
v
d
1
fi
i
3
d
s
i
i
i
a
p
fi
a
t
F death
1 bars
T
F
F
F
N
1535JACC Vol. 45, No. 9, 2005 Kobashigawa et al.
May 3, 2005:1532–7 Heart Transplant Multicenter IVUS Study.048 by the Fisher exact test), percutaneous cardiac inter-
ention (17% vs. 4%, p  0.044 by the Fisher exact test),
efibrillator (4% vs. 2%), cerebral vascular accident (4% vs.
%), and peripheral vascular disease (13% vs. 3%).
Within the five-year follow-up period, there were more
ndings of newly occurring angiographic luminal irregular-
ties in group 1 compared with group 2 patients (65.2% vs.
2.6%, p  0.004). However, there was no significant
ifference between groups for new coronary lesion 50%
tenosis (21% vs. 14%).
igure 2. Kaplan-Meier curve of nonfatal major adverse cardiac events and
 MIT change 0.5 mm; group 2  MIT change 0.5 mm. Vertical
able 2. First-Year Results for Baseline to 1 Year of IVUS Meas
IVUS Measurements
D
G
irst-year change in maximal intimal thickness from baseline
0.5 mm (group 2, N  101)
0.5 mm (group 1, N  24)
p value*
Log-rank p value (Survival curve)
irst-year change in maximal intimal area from baseline
3.5 mm2 (N  107)
3.5 mm2 (N  18)
p value*
irst-year change in percent area of stenosis from baseline
20% (N  108)
20% (N  17)
p value*ote: the reduced N for new luminal irregularities are because some had baseline irregularOther first-year IVUS measurements, including change
n maximal IA (vasculopathy group 3.5 mm2) and change
n percent area stenosis (vasculopathy group 20%) were
nvestigated as surrogate markers of outcome. Patients with
first-year change in maximal IA 3.5 mm2 or a change in
ercent area stenosis 20% had a significantly higher
ve-year incidence of D/GL, NF-MACE and/or D/GL,
nd new angiographic luminal irregularities (Table 2).
Covariates that could influence outcome, including pa-
ient’s age, gender, weight, cytomegalovirus (CMV) serol-
and/or graft loss by maximal intimal thickness (MIT) classification. Group
  SE.
ents and Subsequent 5-Year Outcome
or
oss
Nonfatal MACE and/or
Death or Graft Loss
Any New
Luminal Irregularity
) 17 (17%) 31/95 (33%)
%) 11 (46%) 15/23 (65%)
07 0.003 0.004
25 0.001 —
) 20 (19%) 34/101 (34%)
%) 8 (44%) 12/17 (71%)
01 0.023 0.011
) 18 (17%) 33/102 (32%)
%) 10 (59%) 13/16 (81%)
01 0.001 0.001urem
eath
raft L
6 (6%
5 (21
0.0
0.0
6 (6%
5 (28
0.0
5 (5%
6 (35
0.0ities. *p value, Cochran-Mantel-Haenszel test stratified by center.
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Heart Transplant Multicenter IVUS Study May 3, 2005:1532–7gy, cold ischemic time, lipid levels, pretransplant CAD,
onor age, and center effects, were examined, and only
onor age, patient weight, and CMV serology were signif-
cant when added to the model in the presence of vascu-
opathy. When corrected for any covariates, vasculopathy
emained a highly significant factor for D/GL, NF-MACE
nd/or D/GL, and new angiographic luminal irregularities
patients with change in MIT 0.5 mm having a two- to
hree-fold higher relative risk).
There was no difference in group 1 compared with group
patients in the percentage of patients experiencing any
reated rejection (75.0% vs. 75.2%; p  0.916) and acute
ejection with ISHLT grade 3A or with hemodynamic
ompromise (70.8% vs. 63.4%; p  0.544).
ISCUSSION
his multicenter IVUS study validates the use of first-year
VUS data as a surrogate marker for poor outcomes after
eart transplantation. It appears that the events that occur in
he donor heart in the first post-transplant year influence
he recipient’s immune response toward the donor heart.
he more insults that occur to the donor coronary vascula-
ure, especially early after transplantation, such as that
hich occurs with donor explosive brain death, recurrent
ow-grade cellular rejections (high biopsy score), donor
pecific antibody production (humoral rejection), and CMV
nfection, the greater the likelihood of developing CAV and
ubsequent decreased survival (6–10). The rapid progres-
ion in first-year intimal thickening as detected by IVUS
ppears to represent the cumulative effects of these adverse
vents that ultimately lead to a poor clinical outcomes.
Conventional risk factors, such as hypercholesterolemia,
ypertriglyceridemia, and diabetes, have been reported to be
ssociated with the development of CAV (11–13). The
esults of this study suggest that only higher one-year
riglyceride levels were associated with greater first-year
ntimal thickening. From the patient demographics, it
ppears that older donors are associated with the develop-
ent of greater intimal thickening in the first year after
ransplantation (and subsequent CAV), which has also been
reviously reported (14). This may possibly be due to
reexisting intimal thickening and more endothelial cell
ysfunction in the coronary arteries of the older donor heart,
hich might lead to subsequent poor outcomes.
Intravascular ultrasound has been recognized as a sensi-
ive tool to assess the anatomy of the epicardial coronary
rteries, including intimal and adventitial wall thickness.
he procedure is performed at the time of the routinely
cheduled angiogram and has been demonstrated to be safe
nd have reproducible findings (15–17). An early study
erformed within six to eight weeks after transplantation
llows one to assess donor-transmitted, or “baseline,” ath-
rosclerosis. Serial follow-up imaging with careful site
atching at one year provides important information on theevelopment of CAV. It has been reported that the first- (ear IVUS results render the greatest amount of intimal
hickening compared with the other early years after trans-
lantation (18).
In CAV, MIT, defined as the greatest distance from the
ntimal leading edge to the external elastic membrane, has
een shown to be a clinically useful measurement because of
ts high reproducibility and reported use in predicting
utcome in transplant recipients. The threshold for an
bnormal MIT in subjects with no clinical or angiographic
vidence of significant CAD has been assessed by IVUS.
uzcu et al. (19) performed IVUS in 262 heart transplant
ecipients (mean age 33.4  13.2 years) at 30.9  13.2 days
fter transplantation to assess coronary arteries in young
ubjects (donor hearts). In this study, extensive ultrasound
maging was performed in all three coronary arteries. From
any sites that were analyzed for a given patient, the site
ith the smallest intimal thickness was taken as the repre-
entative of normal. All of the 262 subjects had at least one
ite with an intimal thickness 0.5 mm. Thus, 0.5 mm
hickness was accepted as a threshold for the definition of
therosclerosis for all ages.
One of the first studies to report an association between
utcome and IVUS data came from Mehra et al. (2) at the
chsner Clinic. In this report of 74 patients, those with
evere intimal thickening (0.5 mm) had more events
death, myocardial infarction, and retransplantation), with
pproximately four years of follow-up. Rickenbacher et al.
3) reported an increased cardiac event rate in 145 patients
ith a mean intimal thickening of0.3 mm. This study was
cross-sectional design performing IVUS on patients at 1 to
0 years after transplantation. During a mean follow-up
ime of 48 months, patients with a mean intimal thickness
f 0.3 mm had significantly worse four-year overall
urvival (73% vs. 96%, p  0.005) and cardiac survival (79%
s. 96%, p  0.005). A mean intimal thickness by IVUS of
0.3 mm was associated with an inferior clinical outcome,
egardless of the presence of angiographic CAV, and pre-
icted the development of subsequent angiographic CAV.
oth of these studies, however, did not have a baseline
VUS procedure performed early after transplantation, and
herefore, preexisting donor disease may have been present.
One IVUS study assessed the change in intimal thicken-
ng from baseline to one year and compared these findings
ith long-term outcome. Kapadia et al. (1) reported the
mpact of rapidly progressive intimal thickening (0.5 mm
ncrease in intimal thickening) in the first year of transplan-
ation in 100 transplant recipients. In 43 months of mean
ollow-up, patients with first-year rapidly progressive inti-
al thickening had more subsequent events (death, myo-
ardial infarction, and heart failure) compared with patients
ith no evidence of rapidly progressive intimal thickening
25% vs. 11%). The results of the current multicenter study
re consistent with this previous report. In addition, the
urrent study correlates early intimal thickening to the
ubsequent development of angiographically detected CAV
any luminal irregularity).
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May 3, 2005:1532–7 Heart Transplant Multicenter IVUS StudyThe current study demonstrates consistency in other
VUS parameter data results. Not only was MIT predictive
f poor outcome, but also the first-year change in maximal
A and the change in percent area stenosis. This is the first
eport of these latter two IVUS parameters being predictive
f subsequent poor outcome after heart transplantation.
onclusions. The results of this multicenter study suggest
hat progression of maximal intimal thickening0.5 mm in
he first year (change from baseline to one year) after
ransplantation appears to be a reliable surrogate marker for
ubsequent mortality, NF-MACE, and the development of
ngiographic CAV up to five years after heart transplanta-
ion. These data demonstrate the need to focus on new
trategies during the first year after transplantation to alter
AV disease progression, as well as the need for IVUS to
otentially become more of a standard in the field.
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